GovWire

Sanofi Pasteur COVID-19 vaccine authorised by MHRA

Medicines Healthcare Products Regulatory Agency

December 21
05:52 2022

VidPrevtyn Beta, the COVID-19 vaccine developed by Sanofi, has been authorised by the Medicines and Healthcare products Regulatory Agency (MHRA).

It becomes the seventh COVID-19 vaccine authorised by the UKs independent medicines regulator, following expert advice from the governments independent scientific advisory body, the Commission on Human Medicines.

VidPrevtyn Beta combines the spike protein from a COVID virus variant, Beta, with an adjuvant an additional ingredient designed to trigger a stronger immune response.

The clinical evidence for this authorisation is based on data from about 800 individuals previously immunised with an mRNA or viral-vectored vaccine.

The vaccine demonstrated a strong immune response. The most common side effects observed were mild and self-resolved within a few days of vaccination.

The authorisation is for the use of this vaccine in those aged 18 and over, as a heterologous booster dose, given as a single injection. This means that those who received a different vaccine (mRNA or viral-vectored) as a primary course, can receive this vaccine as a booster.

As with all vaccines, people with an allergy to one of the components listed in the patient information leaflet should not receive the vaccine.

Notes to Editor

Related Articles

Comments

  1. We don't have any comments for this article yet. Why not join in and start a discussion.

Write a Comment

Your name:
Your email:
Comments:

Post my comment

Recent Comments

Follow Us on Twitter

Share This


Enjoyed this? Why not share it with others if you've found it useful by using one of the tools below: